PMID- 20886213
OWN - NLM
STAT- MEDLINE
DCOM- 20101029
LR  - 20211020
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Print)
IS  - 0344-5704 (Linking)
VI  - 66
IP  - 6
DP  - 2010 Nov
TI  - Optimizing ixabepilone treatment schedules in patients with advanced or 
      metastatic breast cancer.
PG  - 1005-12
LID - 10.1007/s00280-010-1467-x [doi]
AB  - The epothilone B analog, ixabepilone, demonstrates low susceptibility to drug 
      resistance mechanisms and has demonstrated clinically meaningful efficacy in 
      patients refractory to other chemotherapeutic options. Ixabepilone is approved by 
      the FDA for treatment of patients with metastatic breast cancer (MBC) progressing 
      after taxanes and anthracyclines, either in combination with capecitabine or as 
      monotherapy if the patient has already progressed on capecitabine. Ixabepilone is 
      generally well tolerated at the approved dose and administration schedule of 40 
      mg/m(2) every 3 weeks. The most commonly observed dose-limiting adverse events 
      (AEs) associated with ixabepilone are myelosuppression and peripheral neuropathy. 
      Dose modification including dose reduction and dosing schedule modification may 
      be utilized to manage toxicities, but this must be based on careful hematologic, 
      neurologic, and liver function monitoring. Other ixabepilone dose schedules are 
      being evaluated to further improve the risk/benefit profile. Weekly and daily 
      schedules of ixabepilone have shown useful efficacy and reasonable tolerability. 
      A recent phase II trial compared the tolerability of ixabepilone dosed once 
      weekly (16 mg/m(2) on Days 1, 8, and 15 of each 28-day cycle) or every 3 weeks 
      (40 mg/m(2) on Day 1 of each 21-day cycle) in patients with MBC. Preliminary data 
      showed that both dosing schedules had an acceptable safety profile; however, more 
      AEs were reported in patients receiving ixabepilone every 3 weeks. Ixabepilone is 
      also being evaluated in combination with other anticancer agents (e.g., 
      bevacizumab and lapatinib), in earlier breast cancer settings and in other 
      indications.
FAU - Egerton, Nancy
AU  - Egerton N
AD  - Pharmacy Services, New York Oncology Hematology, 400 Patroon Creek Blvd, Ste 1, 
      Albany, NY 12206, USA. Nancy.Egerton@usoncology.com
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20101001
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Epothilones)
RN  - 0 (Quinazolines)
RN  - 0 (Tubulin Modulators)
RN  - 0VUA21238F (Lapatinib)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - K27005NP0A (ixabepilone)
RN  - U3P01618RT (Fluorouracil)
RN  - UEC0H0URSE (epothilone B)
SB  - IM
MH  - Antibodies, Monoclonal/administration & dosage
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bevacizumab
MH  - Bone Marrow/drug effects
MH  - Breast Neoplasms/*drug therapy/*pathology
MH  - Capecitabine
MH  - Clinical Trials, Phase II as Topic
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Disease Progression
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Epothilones/*administration & dosage/adverse effects/chemistry
MH  - Female
MH  - Fluorouracil/administration & dosage/analogs & derivatives
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Lapatinib
MH  - Lymphatic Metastasis
MH  - Peripheral Nervous System Diseases/chemically induced
MH  - Quinazolines/administration & dosage
MH  - Treatment Failure
MH  - Treatment Outcome
MH  - Tubulin Modulators/*administration & dosage/adverse effects
PMC - PMC2955910
EDAT- 2010/10/05 06:00
MHDA- 2010/10/30 06:00
PMCR- 2010/10/01
CRDT- 2010/10/02 06:00
PHST- 2010/05/17 00:00 [received]
PHST- 2010/09/09 00:00 [accepted]
PHST- 2010/10/02 06:00 [entrez]
PHST- 2010/10/05 06:00 [pubmed]
PHST- 2010/10/30 06:00 [medline]
PHST- 2010/10/01 00:00 [pmc-release]
AID - 1467 [pii]
AID - 10.1007/s00280-010-1467-x [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2010 Nov;66(6):1005-12. doi: 
      10.1007/s00280-010-1467-x. Epub 2010 Oct 1.